Cargando…

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Effectiveness of China’s 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dan, Zhang, Yanyang, Tang, Lin, Wang, Fuzhen, Ye, Ying, Ma, Chao, Zheng, Hui, Yu, Wenzhou, Cao, Lei, Song, Yifan, Reyimu, Abuduwaili, Zhang, Xiaoxiao, Wang, Haifeng, Nie, Yifei, Lu, Mingxia, Qi, Muge, Li, Jun, Wang, Ruolin, Yang, Kaichao, Wang, Changshuang, Rodewald, Lawrence Everett, Gao, Geroge Fu, An, Zhijie, Yin, Zundong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837442/
https://www.ncbi.nlm.nih.gov/pubmed/35186369
http://dx.doi.org/10.46234/ccdcw2022.009
_version_ 1784649909570371584
author Wu, Dan
Zhang, Yanyang
Tang, Lin
Wang, Fuzhen
Ye, Ying
Ma, Chao
Zheng, Hui
Yu, Wenzhou
Cao, Lei
Song, Yifan
Reyimu, Abuduwaili
Zhang, Xiaoxiao
Wang, Haifeng
Nie, Yifei
Lu, Mingxia
Qi, Muge
Li, Jun
Wang, Ruolin
Yang, Kaichao
Wang, Changshuang
Rodewald, Lawrence Everett
Gao, Geroge Fu
An, Zhijie
Yin, Zundong
author_facet Wu, Dan
Zhang, Yanyang
Tang, Lin
Wang, Fuzhen
Ye, Ying
Ma, Chao
Zheng, Hui
Yu, Wenzhou
Cao, Lei
Song, Yifan
Reyimu, Abuduwaili
Zhang, Xiaoxiao
Wang, Haifeng
Nie, Yifei
Lu, Mingxia
Qi, Muge
Li, Jun
Wang, Ruolin
Yang, Kaichao
Wang, Changshuang
Rodewald, Lawrence Everett
Gao, Geroge Fu
An, Zhijie
Yin, Zundong
author_sort Wu, Dan
collection PubMed
description WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Effectiveness of China’s 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). During an outbreak in Guangdong, inactivated vaccine effectiveness (VE) against the Delta variant was 70% for symptomatic infection and 100% for severe COVID-19. However, separate or combined VE estimates for the two inactivated vaccines against Delta are not available. WHAT IS ADDED BY THIS REPORT? In an outbreak that started in a hospital, VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant were 51%, 61%, and 82%. Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%. VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar, and partial vaccination was ineffective. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Completion of the completed primary vaccination with two doses is necessary for protection from Delta.
format Online
Article
Text
id pubmed-8837442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-88374422022-02-18 Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021 Wu, Dan Zhang, Yanyang Tang, Lin Wang, Fuzhen Ye, Ying Ma, Chao Zheng, Hui Yu, Wenzhou Cao, Lei Song, Yifan Reyimu, Abuduwaili Zhang, Xiaoxiao Wang, Haifeng Nie, Yifei Lu, Mingxia Qi, Muge Li, Jun Wang, Ruolin Yang, Kaichao Wang, Changshuang Rodewald, Lawrence Everett Gao, Geroge Fu An, Zhijie Yin, Zundong China CDC Wkly Preplanned Studies WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Effectiveness of China’s 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). During an outbreak in Guangdong, inactivated vaccine effectiveness (VE) against the Delta variant was 70% for symptomatic infection and 100% for severe COVID-19. However, separate or combined VE estimates for the two inactivated vaccines against Delta are not available. WHAT IS ADDED BY THIS REPORT? In an outbreak that started in a hospital, VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant were 51%, 61%, and 82%. Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%. VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar, and partial vaccination was ineffective. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Completion of the completed primary vaccination with two doses is necessary for protection from Delta. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022-01-28 /pmc/articles/PMC8837442/ /pubmed/35186369 http://dx.doi.org/10.46234/ccdcw2022.009 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Preplanned Studies
Wu, Dan
Zhang, Yanyang
Tang, Lin
Wang, Fuzhen
Ye, Ying
Ma, Chao
Zheng, Hui
Yu, Wenzhou
Cao, Lei
Song, Yifan
Reyimu, Abuduwaili
Zhang, Xiaoxiao
Wang, Haifeng
Nie, Yifei
Lu, Mingxia
Qi, Muge
Li, Jun
Wang, Ruolin
Yang, Kaichao
Wang, Changshuang
Rodewald, Lawrence Everett
Gao, Geroge Fu
An, Zhijie
Yin, Zundong
Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
title Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
title_full Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
title_fullStr Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
title_full_unstemmed Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
title_short Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
title_sort effectiveness of inactivated covid-19 vaccines against symptomatic, pneumonia, and severe disease caused by the delta variant: real world study and evidence — china, 2021
topic Preplanned Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837442/
https://www.ncbi.nlm.nih.gov/pubmed/35186369
http://dx.doi.org/10.46234/ccdcw2022.009
work_keys_str_mv AT wudan effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT zhangyanyang effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT tanglin effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT wangfuzhen effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT yeying effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT machao effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT zhenghui effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT yuwenzhou effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT caolei effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT songyifan effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT reyimuabuduwaili effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT zhangxiaoxiao effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT wanghaifeng effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT nieyifei effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT lumingxia effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT qimuge effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT lijun effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT wangruolin effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT yangkaichao effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT wangchangshuang effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT rodewaldlawrenceeverett effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT gaogerogefu effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT anzhijie effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021
AT yinzundong effectivenessofinactivatedcovid19vaccinesagainstsymptomaticpneumoniaandseverediseasecausedbythedeltavariantrealworldstudyandevidencechina2021